Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
Status:
Completed
Trial end date:
2017-12-18
Target enrollment:
Participant gender:
Summary
Primary:
• To validate the initial dosing recommendations for newly diagnosed MM (Mutiple Myeloma)
patients with various degrees of renal failure using pharmacokinetic studies
Secondary:
- To evaluate the safety of lenalidomide and dexamethasone as induction therapy in
newly-diagnosed MM (Multiple Myeloma) patients with renal dysfunction using modified
dosing guidelines
- To evaluate clinical response of lenalidomide and dexamethasone after 4 cycles using the
modified dosing guidelines
- To evaluate the ability to collect stem cells after 4 cycles of lenalidomide and
dexamethasone induction therapy in MM (Multiple Myeloma) patients with renal failure